GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Suraksha Diagnostic Ltd

Suraksha Diagnostic Q2 FY27 PAT up 69% to ₹149.50 million, Total Income ₹1,005.75 million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 10 Nov 2026, 05:16 PM IST  ·  BSE ID: d5eeaa6d-53c8-4a2c-ad5e-2f8c19f9730e
View Original BSE Filing (PDF)
💡
In Simple Terms
The diagnostic company reported significantly higher profits and revenue for the quarter and half-year ending September 2026.
🤖 AI Summary
  • Q2 FY27 Profit After Tax (PAT) increased 69% year-on-year to ₹149.50 million.
  • Total Income for Q2 FY27 grew 26% year-on-year, reaching ₹1,005.75 million.
  • EBITDA for Q2 FY27 rose 45% year-on-year to ₹363.17 million.
  • Half-year FY27 (H1 FY27) PAT grew 54% year-on-year to ₹277.96 million.
  • Suraksha Diagnostic added five new centers in Q2 FY27, comprising two hubs and three spokes.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Q2 FY27 Total Income
1,005.75 million
26%
Q2 FY27 EBITDA
363.17 million
45%
Q2 FY27 PAT
149.50 million
69%
H1 FY27 Total Income
1,893.09 million
24%
H1 FY27 EBITDA
678.47 million
37%
H1 FY27 PAT
277.96 million
54%
Q2 FY27 EBITDA Margin
36.7%
Q2 FY27 PAT Margin
15.1%
🏢 How This Affects the Company
📈
Business Impact
The company's business pipeline expanded with the addition of five new centers, strengthening its presence across West Bengal and supporting future market expansion. Growth in patient and test volumes indicates increased service utilization.
💰
Financial Impact
Robust growth in Total Income, EBITDA, and PAT suggests improved financial performance and profitability margins in Q2 FY27 and H1 FY27. EBITDA Margin rose from 31.7% to 36.7% in Q2 FY27, and PAT Margin increased from 11.2% to 15.1%.
⚙️
Operational Impact
Operational expansion continued with the commissioning of five new centers, two hub and three spoke, contributing to overall growth. The company reported a 12% year-on-year increase in Total Patients for Q2 FY27, reaching 0.42 million.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's financial performance influences its intrinsic value. Strong profit growth benefits all equity holders.
🔍
Management Signal
Management is signaling a continued focus on revenue growth, profitability enhancement through margin improvement, and strategic network expansion into new markets.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — assess sustained growth in Total Income and PAT margins.
Update on new center additions — track further network expansion and operational metrics.
Progress in Suraksha Genomics — monitor contribution from this early-stage segment.
LOW RISK The filing reports strong financial performance and continued operational expansion without flagging new risks.
💡 Investor Takeaway
Suraksha Diagnostic reported Q2 FY27 Total Income of ₹1,005.75 million, a 26% year-on-year increase, with Profit After Tax rising 69% to ₹149.50 million. H1 FY27 PAT stood at ₹277.96 million, up 54% year-on-year. The company added five new centers during the quarter.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 Profit After Tax (PAT) grew 69% year-on-year to ₹149.50 million, demonstrating increased profitability.
  • EBITDA Margin improved to 36.7% in Q2 FY27 from 31.7% in Q2 FY26, indicating enhanced operational efficiency.

⚠️ Concerns

  • Tests per patient decreased slightly to 5.50 in Q2 FY27 from 5.83 in Q2 FY26, suggesting fewer tests per individual.
  • Growth in Total tests for Q2 FY27 was 5% year-on-year to 2.32 million, lower than revenue growth rates.
📅 Company Track Record
In Q4 FY26, Suraksha Diagnostic reported a 25% year-on-year revenue growth to INR 822 million, with full-year FY26 revenue increasing by 22.5%. This current Q2 FY27 filing shows a continuation of robust growth trajectory.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Suraksha Diagnostic's Profit After Tax (PAT) in Q2 FY27?
Suraksha Diagnostic's Profit After Tax (PAT) for Q2 FY27 was ₹149.50 million, marking a 69% year-on-year increase from ₹88.28 million in Q2 FY26.
What was Suraksha Diagnostic's Total Income for Q2 FY27?
For Q2 FY27, Suraksha Diagnostic's Total Income was ₹1,005.75 million, which represents a 26% year-on-year growth compared to ₹795.80 million in Q2 FY26.
How many new centers did Suraksha Diagnostic open in Q2 FY27?
Suraksha Diagnostic opened five new centers during Q2 FY27, which included two hub centers and three spoke centers.
What is Suraksha Diagnostic's EBITDA Margin for Q2 FY27?
Suraksha Diagnostic's EBITDA Margin for Q2 FY27 stood at 36.7%, an increase from 31.7% in the prior year's comparable quarter.
What were the Total Patients for Suraksha Diagnostic in H1 FY27?
Suraksha Diagnostic served 0.80 million Total Patients in H1 FY27, an increase of 12% year-on-year from 0.71 million in H1 FY26.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.